MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Calderasib
BIOLOGICAL: MK-3475A
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC